In cancer, dysregulated integrin signaling, often driven by aberrant expression or activation of specific integrin subunits such as ITGAV, contributes to tumor progression, metastasis, and treatment resistance [10, 11, 12, 13, 14, 15]. This evidence concerns the gene ITGAV and neoplasm.